速递｜礼来口服GLP-1，启动骨关节炎疼痛三期临床

Core Viewpoint - The article discusses the Phase 3 clinical trial of Orforglipron, a small molecule GLP-1 receptor agonist, aimed at treating obesity in patients with knee osteoarthritis, highlighting its potential efficacy and safety [2][3]. Group 1: Clinical Trial Details - The Phase 3 study, titled "A Phase 3 Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee," will enroll approximately 800 participants [3]. - The study is expected to start in September 2025 and complete by May 2028, with a primary endpoint focused on WOMAC pain scores [3]. - Orforglipron has previously shown positive results in Phase 3 trials for type 2 diabetes and obesity, and it is preparing for market application, marking it as the first small molecule GLP-1 receptor agonist globally [2][3]. Group 2: GLP-1 Drug Overview - GLP-1 (Glucagon-Like Peptide-1) is a hormone produced by intestinal L cells, classified as an incretin, which enhances insulin secretion and suppresses glucagon secretion in a glucose-dependent manner [13]. - GLP-1 receptor agonists are a new class of hypoglycemic drugs that also delay gastric emptying and reduce food intake through central appetite suppression, contributing to blood sugar reduction and weight loss [13].